Regenxbio Inc
RGNX8.365USD
+0.175+2.14%
Horário de mercado （ET）Cotações atrasadas em 15 min
419.23MValor de mercado
PerdaP/L TTM
Mais detalhes de Regenxbio Inc Empresa
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Informações da empresa
Código da empresaRGNX
Nome da EmpresaRegenxbio Inc
Data de listagemSep 17, 2015
CEOMr. Curran M. Simpson
Número de funcionários353
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 17
Endereço9804 Medical Center Drive
CidadeROCKVILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20850
Telefone12405528181
Sitehttps://regenxbio.com/
Código da empresaRGNX
Data de listagemSep 17, 2015
CEOMr. Curran M. Simpson
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
58.87K
--
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
31.47K
-13.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
17.82K
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Dr. David C. (Dave) Stump, M.D.
Dr. David C. (Dave) Stump, M.D.
Independent Director
Independent Director
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
58.87K
--
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
31.47K
-13.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Redmile Group, LLC
9.52%
BlackRock Institutional Trust Company, N.A.
7.77%
The Vanguard Group, Inc.
6.89%
JP Morgan Asset Management
5.85%
Fox (Allan Mark)
5.76%
Other
64.21%
Investidores
Investidores
Proporção
Redmile Group, LLC
9.52%
BlackRock Institutional Trust Company, N.A.
7.77%
The Vanguard Group, Inc.
6.89%
JP Morgan Asset Management
5.85%
Fox (Allan Mark)
5.76%
Other
64.21%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
29.45%
Investment Advisor
29.40%
Hedge Fund
17.30%
Research Firm
8.25%
Individual Investor
7.69%
Sovereign Wealth Fund
2.96%
Pension Fund
0.32%
Bank and Trust
0.25%
Family Office
0.10%
Other
4.27%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
421
48.24M
95.74%
-3.52M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
2023Q3
439
43.73M
99.56%
-6.26M
2023Q2
439
43.86M
100.57%
-5.31M
2023Q1
456
44.07M
101.46%
-1.49M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Redmile Group, LLC
4.79M
9.52%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.92M
7.77%
+48.66K
+1.26%
Mar 31, 2025
The Vanguard Group, Inc.
3.47M
6.89%
+495.83K
+16.65%
Mar 31, 2025
JP Morgan Asset Management
2.95M
5.85%
+36.88K
+1.27%
Mar 31, 2025
Fox (Allan Mark)
2.90M
5.76%
+7.77K
+0.27%
May 30, 2025
Morgan Stanley & Co. LLC
1.57M
3.11%
+45.10K
+2.96%
Mar 31, 2025
Balyasny Asset Management LP
1.40M
2.78%
+211.40K
+17.81%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.15M
2.28%
-23.70K
-2.02%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.11M
2.2%
+12.72K
+1.16%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.09M
2.17%
-19.59K
-1.76%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
WisdomTree BioRevolution Fund
1.81%
iShares Neuroscience and Healthcare ETF
0.92%
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
Global X Genomics & Biotechnology ETF
0.48%
JPMorgan Fundamental Data Science Small Core ETF
0.34%
ALPS Medical Breakthroughs ETF
0.28%
SPDR S&P Biotech ETF
0.13%
iShares Health Innovation Active ETF
0.08%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
Fidelity Enhanced Small Cap ETF
0.07%
Ver Mais
WisdomTree BioRevolution Fund
Proporção1.81%
iShares Neuroscience and Healthcare ETF
Proporção0.92%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.72%
Global X Genomics & Biotechnology ETF
Proporção0.48%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.34%
ALPS Medical Breakthroughs ETF
Proporção0.28%
SPDR S&P Biotech ETF
Proporção0.13%
iShares Health Innovation Active ETF
Proporção0.08%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.07%
Fidelity Enhanced Small Cap ETF
Proporção0.07%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
